Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 72-year-old man with Wolff-Parkinson-White syndrome and sick sinus syndrome had colon cancer, suggesting that the conduction of the Kent bundle depends on the serum potassium level. Because of severe diarrhea or furosemide administration, the serum potassium level in this patient was sometimes low. When it was less than 3.0 mEq/l delta wave or re-entrant tachycardia via the Kent bundle occurred. These were suppressed by the administration of potassium. On the other hand, when the serum potassium level was normal or high, neither effect was noted, and electrophysiological studies, done when the level was 3.2 mEq/l, showed no evidence of conduction by the accessory pathway. This suggests that conduction through the Kent bundle depends on the serum potassium level.
 ...
PMID:A case of Wolff-Parkinson-White syndrome: conduction through the Kent bundle seems to depend on the serum potassium level. 404 52

The irritable colon syndrome is a very common disorder with no serious sequelae. The cause is unknown but low dietary bulk and psychological factors are believed important. Sufferers may experience various combinations of diarrhea, constipation and abdominal pain. The mechanisms are obscure but abnormal colon motility has been amply demonstrated. Serious organic diseases such as colitis and carcinoma of the colon must be firmly excluded. Treatment consists of sympathetic explanation and reassurance, increased dietary bulk and occasional judicious use of antispasmodic agents.
 ...
PMID:The irritable colon. 461 5

Two cases of ulcerative colitis in the Bantu are reported. One patient presented with fulminant acute colitis with toxic dilatation of the colon and massive rectal haemorrhage, the second with chronic, continuous diarrhoea for over twenty years, culminating ultimately with carcinoma of the colon. The aetiology of ulcerative colitis is discussed, together with the problems of specific diagnosis encountered in a population with a high incidence of parasitic infestation and infective diarrhoea. It is considered that the sparseness of reports and apparent rarity of this disease in the Bantu may reflect a failure of detection rather than a true infrequent occurrence. The natural incidence of the disease may be on the increase.
 ...
PMID:Ulcerative colitis in the South African Bantu. 531 8

Both DFMO and methyl-GAG inhibit sequential enzymatic reactions in the pathway of polyamine biosynthesis. Since polyamines may be important factors in proliferation of cancer cells, we initiated a phase-I study of these agents in patients with advanced cancer. DFMO was given by mouth at a constant daily dose of 4 g/m2 starting on day 1 of the treatment protocol. The dose of methyl-GAG ranged from 200 to 700 mg/m2 administered IV every 2 weeks beginning on day 4. Twenty-two patients were entered into the protocol. Toxic reactions to this therapy were dose-related and included nausea, fatigue, diarrhea, and myelosuppression. One patient with colon cancer experienced a greater than 50% decrease in measurable disease but developed severe myelotoxicity. While DFMO was well tolerated, the combination of drugs appeared to cause substantially more hematologic and gastrointestinal toxicity than encountered during our recent experience with methyl-GAG used alone. We suggest that future studies of this drug combination carefully evaluate levels of polyamines and inhibition of enzymatic activity to minimize toxicity.
 ...
PMID:Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)]. 641 31

A phase II study of KW 2083 [7-N-(p-Hydroxyphenyl)-Mitomycin C] was carried out in 14 cases of stomach cancer, 5 of lung cancer, 5 of colon cancer and 5 other types of cancer. KW 2083 was intravenously injected at a dose of 40 mg/body weekly in 26 cases. Among 23 evaluable cases, partial response was obtained in 6 cases (26%). The PR cases were 4 of stomach cancer and 2 of lung cancer, the former being all undifferentiated adenocarcinoma. Regarding hematologic toxicities, thrombocytopenia was the most principal toxicity and an important weak point of KW 2083. Thrombocytopenia (less than 75,000/mm3) was observed in 13 cases (50%). Recovery took about 4 weeks, but by that time 3 cases had still not recovered to 75,000/mm3. leukocytopenia (less than 3,000/mm3) was observed in 17 cases (65%). Concerning gastrointestinal symptoms, anorexia occurred in 11 cases (42%), nausea and vomiting in 11 cases (42%), diarrhea in 1 case and stomatitis in 1 case. T1/2 (beta-phase) of KW 2083 was half that of Mitomycin C.
 ...
PMID:[Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers]. 650 15

A Phase I trial of tricyclic nucleoside phosphate (1,4,5,6,8-pentaazaacenaphthylene-3-amino-1, 5-dihydro-5-methyl-1-beta-D-ribofuranosyl 5'-phosphate ester; NSC 280594) was conducted using a 5-day continuous infusion schedule. Thirty-seven patients with advanced cancer were entered on the study, of whom 33 patients were evaluable for response and toxicity. Dose levels ranged from 10 mg/sq m/day X 5 days to 40 mg/sq m/day X 5 days. Initially, courses were repeated every 3 to 4 weeks. As cumulative toxicity became manifested, the interval between courses was changed to every 6 weeks. Major toxicities included hyperglycemia, hepatotoxicity, and thrombocytopenia. Patients with a prior history of diabetes mellitus, extensive radiation therapy, or significant liver metastases were prone to severe toxicity. Other toxicities noted were nausea and vomiting, abdominal discomfort, anemia, and reduction in serum calcium, phosphorus, and albumin levels. Rare side effects included hypertriglyceridemia, hyperamylasemia, diarrhea, and stomatitis. Antitumor activity observed include improvement in s.c. metastases in a patient with papillary thyroid carcinoma, stabilization of disease in a patient with mesothelioma, and mixed responses in three patients (colon cancer, sarcoma, and tonsillar squamous cell cancer). Recommended schedule for Phase II studies is 20 mg/sq m/day for 5 days every 6 weeks.
 ...
PMID:Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. 674 83

There is a spectrum of endometrial stromal neoplasms which extends from borderline benign to low-grade malignant. These have a definite tendency to metastasize. Proper diagnosis is important because they have an excellent prognosis with long-term survival even with evidence of recurrence or metastases. Aggressive treatment is mandatory. This represents the first report of the radiographic spectrum of the entity as seen in 7 cases. The patients are usually in middle age and present with vaginal bleeding. Not previously stressed is the presence of diarrhea in many of them. Prior uterine surgery even for "fibroids" should be viewed with suspicion. A pelvic mass was usually seen on plain films, intervenous pyelogram (IVP), or barium enema (BE). Ultrasound showed a mixed cystic configuration of the tumors, whereas computed tomography (CT) demonstrated a definitely solid mass. The lesions simulated primary carcinoma of the colon, retroperitoneal tumor, and pelvic inflammatory disease. Metastases to the lung and the bone were also identified.
 ...
PMID:Endometrial stromal tumors, their varied radiographic patterns. 723 41

Forty-four patients with advanced colon or rectal cancer were treated with methyl-GAG on a weekly schedule. Of the 40 evaluable patients, 35 (87%) had received prior chemotherapy. Objective tumor regression was seen in six patients (one CR, five PR's). An additional nine patients had stable disease for a median of 42 weeks. The median survival (42+ weeks) for responding and stable disease patients was significantly better (p = 0.0001 Wilcoxan test) than those with progressive disease (11 weeks). Toxicity was reversible and included mild to moderate mucositis, nausea, vomiting, diarrhea, and thrombocytopenia. Responses observed in this study warrant further trials in patients with colon cancer who have no prior chemotherapy.
 ...
PMID:Phase I-II trial of methyl-GAG in advanced colon cancer. a Southwest Oncology Group pilot study. 728 75

A 57-year-old male presented with abrupt melena. Numerous polypoid lesions were found in the stomach and colon accompanied by characteristic ectodermal changes of the Cronkhite Canada syndrome. He had undergone a left side hemicolectomy for colon cancer 3 years previously. Two months after the operation, he had noticed hyperpigmentation of the skin, alopecia and chronic diarrhea. Subsequently, after 8 months, the presence of numerous polypoid lesions in the remnant colon and the rectum was established. This is the first reported case in which features of the Cronkhite-Canada syndrome have developed after resection for colon cancer.
 ...
PMID:A case of Cronkhite-Canada syndrome developing after hemi-colectomy. 729 17

Topoisomerase I inhibitors are a new therapeutic class whose clinical evaluation began a few years ago; Irinotecan (CPT-11) gave interesting results in colon cancer; side effects were neutropenia, diarrhea, vomiting and a cholinergic syndrome. Topotecan was useful in lung and ovarian cancer; side effects were mostly hematologic. Undergoing studies concern dose optimization, mode of administration and therapeutic associations.
 ...
PMID:[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]. 749 18


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>